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Abstract
BACKGROUND: The third identified severe respiratory disease in the past two decades and the first to result in a 
pandemic is the coronavirus disease 2019 (COVID-19) specifically caused by the severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2).
AIM: The aim of this study was to provide an overview of the basic pathology and diagnostic laboratory features of 
COVID-19.
METHODS: This review involved search of literatures on PubMed, Science alert, Medline, and Advanced Google 
search using the keywords “SARS-CoV2,” “Coronavirus” along with “pathology of COVID-19” and “diagnosis of 
COVID-19” with related articles pooled, relevant information extracted, and properly referenced.
RESULTS: The recommended method of diagnosis is by nucleic acid testing of the viral ribonucleic acid in which real-
time reverse-transcription polymerase chain reaction followed by nucleic acid sequencing when required is performed 
while some serologic techniques developed include enzyme-linked immunosorbent assay, immunochromatographic 
lateral flow assay, neutralization bioassay, and specific chemosensors to detect the immunoglobulin M and 
immunoglobulin G antibodies produced, although sole use of serologic tests is highly discouraged by monitoring 
agencies. The hematological features display leukocytosis with lymphocytopenia, eosinopenia, reduced procalcitonin 
along with increased D-dimer, C-reactive protein, serum amyloid A, fibrin, fibrin degradation products, and some 
inflammatory markers such as interleukin (IL)-2, IL-6, IL-7, IL-10, granulocyte colony-stimulating factor, MCP10, 
interferon gamma-induced protein 10, and tumor necrosis factor-α. The pathologic presentations include pleurisy, 
lung consolidation, pulmonary edema and pericarditis along with other features of acute respiratory syndrome, 
myocardial injury, and acute kidney injury.
CONCLUSION: There are highly efficacious and reliable methods of diagnosis of COVID-19 which also determine 
the stage and severity of the condition, and these methods are performed in line with specific clinical presentations. 
However, more studies are required to identify the capabilities, characteristics, and tendencies of this novel virus.
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Introduction
Coronavirus disease 2019 (COVID-19), a 
latest outbreak proclaimed as a pandemic by the World 
Health Organization (WHO), is a diseased condition 
resulting from infection of the severe acute respiratory 
syndrome corona virus-2 (SARS-CoV-2) [1]. The 
disease was named on February 11, 2020, by the WHO 
and subsequently declared a pandemic, on March 11, 
2020 [2], [3], when it was recorded that there were more 
than 118,000 cases in 114 countries and 4291 deaths 
as a result of its rapid spread through human to human 
transmission by aerosol droplets to all continents of 
human existence with 13-fold increase [4]. COVID-19 
is the third identified severe respiratory illness caused 
by the coronavirus in the past two decades and the first 
to cause a pandemic [4]. Others such as SARS and 
Middle East respiratory syndrome (MERS) have been 
earlier identified possessing similar susceptibility [5].
SARS-CoV-2 was classified by the International 
Committee on Taxonomy of Viruses (ICTV) as a newly 
identified strain of ribonucleic acid (RNA) viruses 
which had not been previously isolated in humans 
until recently when it was discovered to be transmitted 
from human to human resulting in series of respiratory 
tract disorders, ranging from various levels of severity 
which commenced in Wuhan, China [6], [7], [8], [9]. The 
complete genome sequencing information from two 
assemblage revealed that the SARS-CoV-2 comprises 
six major open reading frames and shares 
approximately 80% of similarity with SARS-CoV, but 
98.65% nucleotide identity to partial RNA-dependent 
RNA polymerase (RdRp) gene and 96.2% identity to 
RaTG13 of SARS-related CoronaVirus family found in 
bats, respectively [6], [10], [11], [12].
Globally, as at July 17, 2020, there have 
been 13,616,593 confirmed cases of COVID-19, 
including 585,727 deaths with 7,154,840; 3,008,972; 
1,346,792; 1, 308,441; 543,122; and 253,495 
confirmed cases in America, Europe, Eastern 
Mediterranean, South-East Asia, Africa, and Western 
pacific continents, respectively [13], [14]. Despite the 
documented comparatively low mortality, the transmissibility 
of COVID-19 is observably elevated [15], [16]. 
This transmissibility potential is the R0 value which 
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is a pointer of the viral ability to transmit, thereby 
representing the average figure of new infections 
produced by an infectious person in a an uninfected 
populace. When R0  >  1, this indicates that there is the 
possibility of increased infection while R0  <  1 indicates 
the fading off of transmission . An essential concept of 
infectious disease epidemiology is the reproduction 
number which indicates the menace associated with 
the endemic spread of an infectious agent [17]. The 
basic reproduction number (R0) of COVID-19 has been 
estimated to range from 1.4 to 6.47, while some studies 
have shown the R0 value to be >3 [16], [17], [18].
The COVID-19 is characterized by various 
degenerative symptoms such as pyrexia, dry or 
hoarse cough, sputum, gasping or cessation of breath, 
loss of taste sensation and/or smell, exhaustion, and 
lymphopenia in infected persons with the infections 
causing viral pneumonia which may lead to SARS 
and mortality in more severe cases or persons 
with underlining conditions such as diabetes and 
hypertension [6], [7], [8], [9], [19].
With the current trend in the management, 
epidemiology and occurrences in this pandemic, this 
review attempts to appraise the pathology, diagnosis, 
and laboratory features of COVID-19.
Methodology
This review involved search of the literatures 
on PubMed, Medline , Science alert, and Advanced 
Google search using the keywords “SARS-CoV2,” 
“Coronavirus” along with “pathology of COVID-19” and 
“diagnosis of COVID-19”in this text with related articles 
pooled and relevant information extracted, and properly 
referenced. From the search, we obtained 205 (220) 
articles out of which relevant information for this study 
were specifically extracted from 96 of the publications 
for this article.
Pathogenesis of COVID-19 infection
Coronaviruses are a family of enveloped single-
stranded RNA viruses with zoonotic features, and clinical 
signs analogous to the regular flu, neurological, severe 
respiratory, hepatic, and gastrointestinal symptoms 
[4], [20]. The six other identified coronaviruses which 
can infect humans aside the SARS-CoV-2 [21], are 
HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, 
HCoV-HKU1, and MERS-CoV [6], [21], [22], [23]. 
They have created two major pandemics in the past 
20 years which are the SARS [24] and MERS [11], 
[21], [25]. In detection of the major source of COVID-
19, China Centre for Disease Control (CDC) analysts 
pointed that it originated from wild animals that are sold 
in the Wuhan local market (Chinese CDC, 2020). The 
researchers obtained and analyzed throat swab, lung 
fluid, and blood samples of 15 patients infected with the 
virus. The analyses discovered that the virus-specific 
nucleic acid sequences in the sample differ from those 
of previously known human coronavirus (hCoV) species 
displaying that SARS-CoV-2 has similar properties to 
some of the beta (β) coronaviruses genera identified 
in bats [8], [11], [26], [27], among the SARS/SARS-like 
CoV group [11], [21].
The outcome of the next-generation sequencing 
performed by these researchers indicated that the 
features of SARS-CoV-2 differ from SARS-CoV (with 
about 79% sequence identity) and MERS-CoV (with 
about 50% sequence identity) than from the group of 
two bat-derived SARS-such as coronaviruses – bat-SL-
CoVZC45 (with 87.9% sequence identity) and bat-SL-
CoVZXC21 (with 87.2% sequence identity) [28]. Studies 
also reported that COVID-19 S-protein supported strong 
relationship with human angiotensin converting enzyme 2 
(ACE2) molecules in spite of the variation in its sequence 
with that of SARS-CoV [11], [21], [29]. Although detailed 
pathogenesis of this novel infection is emerging day by 
day, the mechanism of infection has been described to 
entail the adhesion of the viral spike protein to the ACE2 
molecule of the type II pneumocyte receptor (a precursor 
of type I pneumocyte) and the virion is endocytosed by 
the help of a serine protease TMPRSS2. On entering 
the cell, the virion RNA is released and translated by the 
cells machinery into non-structural polyproteins that are 
cleaved into proteases, which are RNA-dependent, RNA 
polymerases, and structural proteins. Then replication 
complex forms to produce more RNA with viral proteins 
and RNA assembling into a newly manufactured virion in 
the Golgi consequently releasing the virion to infect new 
Type II pneumocytes [30]. This, in turn, result in aggressive 
inflammatory response leading to vascular endothelial 
dysfunction and subsequently endotheliopathy, with 
sepsis-induced coagulopathy (SIC) as described by the 
international society for thrombosis (ISTH) [31], [32]. The 
SIC in COVID-19 could occur by activation of coagulation 
through several procoagulant pathways such as viral 
adhesion on an ACE2 receptor present on endothelial 
cells, inflammatory cell infiltration coupled with apoptosis 
of endothelial cells, and microvascular prothrombotic 
effects [33] which explains the myocardial ischemia and 
increasing reports of macro- and micro-thromboembolic 
complication in some patients [33], [34], [35].
 Furthermore, the pathobiology of this process 
has been further classified into three stages [36] 
which are: The asymptomatic state occurring within 
1–2 days of infection whereby the inhaled virus will 
bind the epithelial cells of the nasal cavity through the 
assistance of the ACE2 receptors with the consequent 
initiation of a limited innate immune response [37], [38]; 
the next stage is symptomatic phase characterized by 
the upper and conducting airway response occurring 
within few days of infection triggering a more robust 
innate immune response evidenced with the presence 
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of beta and lambda interferons, especially C-X-C 
motif chemokine ligand 10, an excellent interferon 
responsive gene to the alveolar type 2 cell in SARS and 
influenza infection. Finally, the third stage is associated 
with hypoxia, ground-glass infiltrate with progression 
to acute respiratory distress syndrome (ARDS) which 
occurs as the virus reaches the gas exchange units 
of the lung infecting the peripheral and subpleural 
alveolar type II cells leading to apoptosis and cell 
death. This, in turn, will trigger a secondary pulmonary 
epithelial regeneration as was seen in influenza 
pneumonia [36], [39], [40]. The recovery will, however, 
require an energetic innate and acquired immune 
response coupled with aggressive pulmonary epithelia 
regeneration which is quite slow in the elderly due to 
their diminished immune response and reduce ability to 
regenerate or repair damaged epithelial cells [36].
Laboratory diagnosis of COVID-19
The diagnosis of the infection is majorly by 
molecular methods whereby reverse-transcriptase 
polymerase chain reaction (RT-PCR) is the choice 
technique [41], [42], [43], [44], [45]; serological tests 
have been developed by CDC (2020) for optimization 
and validation of other serologic reagents manufactured 
for diagnostic purposes. The severity of the condition 
can also be evaluated by the various laboratory 
analyses, across the hematology, chemical pathology, 
histopathology, microbiology and immunology field, so 
as to correlate their results with the clinical manifestation 
in the management of the patients.
Specimens for diagnosis
To ensure accurate diagnosis of the viral 
pneumonia infection (COVID 19), collecting good 
quality and the correct specimen from the patient 
promptly are important. According to the CDC 
guidelines, upper and lower respiratory specimens 
such as throat swab, nasal nasopharyngeal (NP) swab, 
sputum, and bronchial fluid are recommended [46]. In 
patients with more severe respiratory disease, upper 
respiratory specimens such as NP and oropharyngeal 
(OP) swab including lower respiratory specimens such 
as sputum (SP) and endotracheal aspirate or Broncho-
alveolar lavage can be used. Previously, Wang et al. 
reported that OP swabs were used more often than 
NP specimen in China during the COVID-19 outbreak 
and that SARS-CoV-2 RNA was significantly detected 
in NP swabs [47]. The CDC also recommended the 
collection of the upper respiratory swab. Collection of 
an OP specimen was considered of a lower priority and 
when collected may be combined in a single tube as 
the NP swab [46]. Swab specimens are recommended 
to be placed and transported in a universal or viral 
transport medium or stored 2–8°C for up to 72 h after 
collection. Specimens can be stored at −70°C or below 
when a delay in testing or shipping is anticipated [46]. 
In addition, Cheng et al. have recommended the 
collection of both upper and lower respiratory samples 
such as Sputum and Broncho alveolar lavage fluid [48]. 
SARS-CoV-2 has also been detected from urine, 
stool, and blood specimens, although less frequently 
than from respiratory specimens. Cheng et al. publish 
that 70% (n = 38) of the fecal specimen at the peak 
of viral (9–11 days) shedding was positive following 
testing. Furthermore, a case report by Tang et al. have 
recorded a positive test in an asymptomatic child who 
was positive for the 2019 novel coronavirus by rRT-
PCR from stool specimen even 9 days after respiratory 
tract specimens were negative [49]. The use of nucleic 
acid detection of COVID-19 in fecal specimens has 
been appraised to be equally accurate in diagnosis [7]. 
Likewise, the use of serum for the detection of SARS-
CoV-2 has been previously reported. Zhang et al. 
showed that serological tests can improve detection rate 
and recommended its usage in future epidemiological 
studies [50]. Rectal sourced specimens have likewise 
been reported positive in patients infected with SARS-
CoV-2 [51].
Molecular diagnosis
SARS-CoV-2 is a single-stranded positive-
sense RNA virus and its entire genetic sequence 
was uploaded to the Global Initiative on Sharing All 
Influenza Data platform on January 10, 2020. The 
sequence data have since been helpful in designing 
primers and probes useful for the molecular diagnosis 
of SARS-CoV-2 [49], [52]. According to the WHO’s 
guidelines, nucleic acid amplification tests (NAAT) for 
COVID-19 SARS-CoV-2 have been recommended. 
Routinely, confirmation of COVID-19 casesis based 
on detection and analysis of the sequences of virus 
RNA by NAAT such as real-time rRT-PCR, followed up 
by nucleic acid sequencing when required. The viral 
genes usually targeted include the N, E, S, and RdRP 
genes [53]. It is recommended that RNA extraction is 
done avoiding contamination in a biosafety cabinet in 
a BioSafetyLevel-2. Heat treatment of samples before 
RNA extraction is not recommended [54], [55]. A major 
advantage in the use of molecular diagnostic strategy is 
its ability to detect a positive case in an asymptomatic 
population thus preventing the spread of the virus 
to close contact. A study by Mizumoto et al., on the 
passengers (n = 3,711) on a diamond princess cruise 
ship tested for SARS-CoV-2 revealed an estimated 
asymptomatic proportion (among all infected cases) at 
17.9% (95% CrI: 15.5–20.2%) [56].
RT-PCR
RT-PCR is recommended as the gold standard 
detection method for the identification of SARS-CoV-2 
virus and relies on the principle of amplifying a small 
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amount of viral genetic components in a sample. At 
present, RT-PCR test for SARS-CoV-2 has been used 
to test samples collected from the upper respiratory 
system using swabs. There are studies which have 
employed the use of this method in identification of 
SARS-CoV-2 in serum, stool, and other specimens 
[57], [58]. Although RT-PCR is the most widely used 
method for detecting SARS-CoV-2 infections, its 
major limitation is that it requires expensive laboratory 
instrumentation and reagents as well as highly skilled 
laboratory personnel to man such laboratories. Thus, a 
number of companies and laboratories around the globe 
are working on means of improving the efficiency and 
timeliness of the RT-PCR technologies and developing 
various other diagnostic methods [52].
Other molecular techniques in use include: 
Isothermal nucleic acid amplification which allows gene 
amplification at a constant temperature and eliminates 
the need for a thermal cycler [59]. This principle is 
used in reverse-transcription loop-mediated isothermal 
amplification (RT-LAMP). RT-LAMP provides an 
alternative and a more rapid and cost-effective testing 
method for SARS-CoV-2 but requires a set of four primers 
to target the genes and enhances the sensitivity of the 
test with a reverse-transcription step to allow for the 
detection of RNA. The amplified product can be detected 
using a photometric apparatus to measure the turbidity 
caused by magnesium pyrophosphate precipitated in 
the solution as a byproduct of amplification [52]. The 
reaction can be monitored in real time by measuring 
the turbidity or fluorescence using intercalating dyes 
since RT-LAMP diagnostic testing requires heating 
and visual inspection. The simplicity and sensitivity of 
this technique make it a promising candidate for virus 
detection [52], [60].
Microarrays have equally provided a rapid 
and high-throughput detection for SARS-CoV-2 nucleic 
acids. This technology relies on the use of reverse 
transcription to generate complementary DNA (cDNA) 
from viral RNA and subsequently labeling the cDNA with 
specific probes. In principle, the arrays are prepared 
either by an in situ synthesis of biomacromolecules 
on solid substrates or by spotting ex situ synthesized 
biomacromolecules on a substrate surface [61]. This is 
followed by loading the labeled cDNAs into the wells of 
microarray trays containing solid-phase oligonucleotides 
attached onto their surfaces. If hybridized and after 
washing away the unbound DNA, they remain bound, 
signifies the presence of virus-specific nucleic acid [41]. 
The use of microarray assay has been previously 
reported and identified as a useful tool in detecting 
mutations associated with SARS-CoV-2 [53], [54]. Guo 
et al. detected and characterized viral strains with 100% 
accuracy and thus recommended this method for the 
detection and epidemiological surveillance for SARS-
CoV-2 [62], [63]. At present, more studies are needed to 
further substantiate and to evaluate the sensitivity of this 
method in SARS-CoV-2 diagnosis especially in Africa.
Serological and Immunological assays
Serologic assays have important public 
health applications in the current COVID-19 response. 
RT-PCR-based viral RNA identification has been used 
globally and appraised as the gold standard in diagnosis 
of COVID-19 but has inability to monitor the progress 
of the disease stages and cannot be applied to the 
identification of past infection and immunity [52]. It is 
believed that serologic testing can aid the understanding 
of disease patterns and transmission as well as improve 
data collection from serologic surveys among different 
ethnic groups and populations [64].
Serologic testing involves analysis of blood 
serum or plasma and other biological fluids. In 
principle, it involves recognition of antibodies, which are 
specific proteins produced in response to infections. 
This screening method plays an important role in 
epidemiology and vaccine development. It also provides 
an assessment of both short-term (days to weeks) 
and long-term (years) trails of antibody response in 
the tested population. Immunoglobulin M (IgM) first 
becomes detectable in serum after few days and lasts 
for some weeks on infection. This is usually followed 
by a switch to immunoglobulin G (IgG). Thus, IgM may 
be used as an indicator for early stage of infection and 
IgG is indicating a current or prior infection. IgG may 
also be used to suggest the presence of post-infection 
immunity. In the recent COVID-19 pandemic, serologic 
tests have been identified to have huge potential for the 
epidemiology of COVID-19 [64].
However, the United States’ CDC has cautioned 
on the direct adoption of serologic testing for SARS-
CoV-2 as more studies are needed to comprehend if 
the antibodies produced from SARS-CoV-2 infection 
will confer immunity from a future infection. CDC 
scientists are conducting studies to better understand 
the level of antibodies needed for protection, the 
duration of such protection, and the factors associated 
with whether a person develops a protective antibody 
response [64]. The U.S. Food and Drug Administration 
(FDA) recommended (revised policy) that the use of 
serologic tests and reagents intended for antibody 
detection to SARS-CoV-2 to identify people who 
may have been exposed to the SARS-CoV-2 virus 
or who have recovered from the COVID-19 infection 
be subjected to validation and approval, it was also 
emphasized that serological (antibody) tests should not 
be used as the sole basis to diagnose COVID-19 [65].
The serologic techniques in use include 
the enzyme-linked immunosorbent assay (ELISA), 
immunochromatographic (ICG) lateral flow assay, 
neutralization bioassay, and specific chemosensors. 
They vary in speed, multiplexing, automation, as well as 
limitations such as requirements for trained personnel 
and availability of dedicated laboratories. The FDA had 
earlier granted emergency use authorization status to 
the first serology test, qSARS-CoV-2 IgG/IgM Rapid 
Test, manufactured by Cellex Inc., on April 1, 2020 [65]. 
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A study by Pan et al. demonstrated the serologic ability 
of ICG strips in identifying SARS-CoV-2 infection to 
be sensitive and consistent and thus considered it 
as an excellent complementary approach in clinical 
application [66]. In another study, Haveri et al. assessed 
the presence of neutralizing antibody response along 
with specific IgM and IgG targeting nucleocapsid and 
spike proteins and recommended this technique has a 
candidate test which can enhance better understanding 
of SARS-CoV-2 infection. However, monitoring of the 
binding antibodies is suggested to be a more sensitive 
method than measuring functional neutralizing antibodies 
for serological detection of hCoV infections [67].
Hematological features and other 
laboratory findings
The hematological analysis reported by 
various researchers include the total leukocyte count, 
lymphocyte, eosinophils, monocyte, platelet counts, 
D-dimer, procalcitonin (PCT), serum amyloid A (SAA), 
erythrocyte sedimentation rate (ESR) and they are 
categorized based on the concentration of parameters, 
severity of disease (severe and non-severe conditions), 5 
and 4-days post-hospital presentation, and complication 
conditions as represented in Table 1 obtained from the 
studies by Zhang et al. and Bingwen et al. [1], [68]. Zhang 
et al. reported that the total leukocyte count, D-dimer, 
C-reactive protein (CRP) (p < 0.001), and SAA were 
increased in patients with severe condition than those 
whose conditions were not severe while decreased 
value was observed in lymphocyte , eosinophils, and 
PCT in severe conditions with observable lymphopenia 
and eosinopenia at 5 days post-clinical presentation. 
The population distribution demonstrated 12.3%, 
43.2%, 34.7%, and 90.2 % of the COVID-19 positive 
population had increased leukocyte, D-dimer, PCT, and 
SAA, respectively, while 19.6 %, 75.4%, and 52.96 % 
had decreased leukocyte, lymphocyte, and eosinophil 
counts, respectively [1]. In addition, corroborating work 
by Bingwey et al. reported similar white cell results 
along with moderate platelet count and hemoglobin 
concentration [68]. Some other studies that relate COVID-
19 infection with thrombosis also observed increased level 
of D-dimer along with increase in some other coagulation 
markers such as fibrin, fibrin degradation products (FDP) 
with minimal change in prothrombin time, activated partial 
thromboplastin time, and platelet count which are pointers 
of thrombosis as reviewed by Connors et al. and Robbin 
et al. [32], [69]. In addition, the assessment of 11 patients 
in the intensive care unit in Italy display reduced mean 
antithrombin concentrations with slightly low protein S 
free antigen along with an increased mean vWF and 
vWF-ristocetin cofactor activity [70]. These observations 
coupled with other severe thrombotic developments led 
the ISTH developing an interim guidance on recognition 
and management of coagulopathy in COVID-19 whereby 
D-dimer, prothrombin time, platelet count, and fibrinogen 
(if fibrinogen measurement is feasible ) are to be measured T
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in patients presenting with COVID-19. The patients with 
abnormal results are to be admitted and subsequent 
treatment (heparin or blood product transfusion) based 
on the severity of results obtained [71].
Furthermore, another study by Shuchang et al. 
on the CT features of COVID-19 infected persons with 
pneumonia in some 62 patients in Wuhan, China, observed 
that the routine blood analyses conducted on 30 of the 
patients displayed 6 (20.0%), 24 (80.0%), and 15 (50.0%) 
with leucopenia, lymphocytopenia, and decreased 
percentage of lymphocytes, respectively [72]. The 
ESR and high-sensitivity CRP level assessed yielded 
66.7% and 100% elevated values for both parameters, 
respectively, thus are corroborating the report of the 
study by Zhang et al. [1]. A usual or diminished total 
white blood cell count along with reduced lymphocyte 
count can be demonstrated in the early phase of 
the infection as researched by Cascella et al. [73]. 
Furthermore, their article reported that lymphopenia is 
visibly negative prognostic factor for COVID-19 infection 
with amplified values of CRP and standard procalcitonin 
value. In severe condition, it was reported that D-dimer 
value is augmented, blood lymphocytes declined 
persistently, and analytical variations of multiple organ 
imbalance evident by high amylase as well as disordered 
coagulation activities [73].
In addition, leukopenia, lymphocytopenia, and 
eosinophil cytopenia were observed to be recurrent 
in COVID-19 induced pneumonia more than those in 
non-COVID-19 induced pneumonia [74]. Furthermore, 
a marked reduction in CD4 and CD8 lymphocytes 
series was noted at the onset phase of the disease by 
Wang et al. [8] with patients in the critical care facility 
displaying higher levels of interleukin (IL) 2, IL-10, IL-7, 
monocyte chemotactic protein 1 (MCP1), granulocyte 
colony-stimulating factor (GCSF), interferon gamma-
induced protein 10 (IP10), tumor necrosis factor-α 
(TNF-α) and macrophage inflammatory protein alpha 
along with other abnormal coagulation, and cell count 
parameters described by some other researchers [7], [75]. 
The lung injury presentation in this infection has been 
strongly analyzed by emerging evidences to result from 
the excessive release of pro-inflammatory markers such 
as IL-1, IL-6, and TNF-α and interferon, a situation called 
cytokine storm [76]. This is because their secretion 
results in influx of immune cells into the site of infection 
producing destructive effects on tissues damaging cell 
interaction, multi-organ failure, and eventual death [77]. 
This is ascertained by the further analysis of cytokines 
in infected patients with the observation that they are 
increased in patients and even more elevated in severe 
cases [7], [78], [79], [80], [81], [82] as well as in children 
from ages 2 months to 15 years [83].
In addition, infected individuals with blood 
Group A were studied to be significantly most-at-risk 
for contracting COVID-19 compared with non-A blood 
groups while blood Group O has a appreciably lower 
risk for the infection compared with non-O blood groups 
as reported by some researchers in Wuhan, China [19]. 
Although, there are still some categorical questions 
concerning the study with regard to the distribution of 
blood groups in China populace, ethnicity, and statistical 
inferences.
Histopathological features of COVID-19
The macroscopic view of COVID-19 is observed 
more to be in the chest and can also include pleurisy, 
lung consolidation, pulmonary edema, and pericarditis. 
The weight of the lung may increase above normal. It can 
also be noted that a secondary infection can be super 
imposed on the viral infection which can lead to purulent 
inflammation that is more of a typical bacterial infection [84]. 
A recent article explained the early pathological features in 
COVID-19 in two patients who had gone through surgical 
resections for lung adenocarcinoma, but it was later 
discovered during the procedure of the operation that the 
two patients had COVID-19 [11]. The findings obtained 
were not specific and these include edema, pneumocyte 
hyperplasia, focal inflammation, and multinucleated 
giant cell formation, while hyaline membranes were not 
observed. These patients did not show any symptoms of 
COVID-19 as at the time of the operation; these are likely 
to reflect only in the early changes of acute lung injury in 
the infection [11].
Furthermore, a reported case of biopsy 
samples from 50 years deceased of COVID-19 in 
Wuhan city, China, was harvested from the liver, lungs, 
and heart organs of the patient. Histomorphological 
examination revealed bilateral diffuse alveolar damage 
with cellular fibromyxoid exudates [85]. The right lung 
revealed evident of desquamation of pneumocytes and 
hyaline membrane formation, which indicates an ARDS. 
The left lung showed pulmonary edema with hyaline 
membrane formation, which suggests of early-phase 
ARDS [85]. Both the right and left lungs also revealed 
interstitial mononuclear inflammatory infiltrates, which 
are dominated by lymphocytes. Multinucleated syncytial 
cells with atypical enlarged pneumocytes, characterized 
by large nuclei, amphophilic granular cytoplasm, and 
prominent nucleoli were observed in the intra-alveolar 
spaces, which showed viral cytopathic like changes [85]. 
There were no obvious intracytoplasmic or intranuclear 
viral inclusions were seen. In addition, the liver biopsy 
specimen of the same patient with COVID-19 revealed 
moderate microvesicular steatosis, mild lobular, and 
portal activity which indicates that the injury might have 
been caused by either SARS-CoV-2 infection or drug 
induced liver injury. There was no other substantial 
damage observed in the heart tissue except a few 
interstitial mononuclear inflammatory infiltrates [85]. 
According to Sufang et al., 2020, who also carried out 
postmortem fine-needle core biopsies on some selected 
organs (liver, heart, and lungs) on four patients who also 
died of COVID-19 pneumonia, each of these patients 
had one or two underlying diseases, which include 
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immunocompromised status (chronic lymphocytic 
leukemia and renal transplantation) or some other 
conditions, which are liver cirrhosis, diabetes, and high 
blood pressure [86]. The time frame from the onset of 
the disease to death for the patients ranged from 15 to 
52 days. The main features observed in their histology 
were in the epithelial tissues, formation of hyaline 
membrane, and hyperplasia of type II pneumocytes, all 
the components of diffuse alveolar damage. Fibroblast 
proliferation with extracellular matrix and fibrin forming 
clusters in airspaces is evident with an abundant intra-
alveolar neutrophilic infiltration, consistent with super 
imposed bacterial bronchopneumonia in one of the 
patients. The liver showed a mild lobular infiltration with 
small lymphocytes and centrilobular sinusoidal dilation 
and a patchy necrosis was also observed [86].
The heart showed only focal mild fibrosis 
and mild myocardial hypertrophy. The postmortem 
examination showed an advanced diffused alveolar 
damage as well as superimposed bacterial pneumonia 
in some of the patients. The histomorphological changes 
observed in the heart and liver were most likely to be 
secondary or caused as a result of the effects of the 
underlying disease [86].
Complications of COVID-19 Infection
Acute respiratory syndrome
The presence of ACE2 on the cells of the 
heart, kidney, and lungs encourages the SARS viruses 
infection [87] and about 42% of COVID-19 patients do 
develop ARDS [88]. Diabetes mellitus is also a factor 
associated with the development of ARDS [78]. Other 
diseases that can cause complications in COVID-19 
patients include hypertension, cardiovascular disease, 
and chronic kidney disease [88], [89]. Medical 
laboratory findings associated with the development 
of ARDS include lymphopenia, neutrophilia, elevated 
CRP, elevated blood urea nitrogen, prolonged 
prothrombin time, elevated d-dimer, and elevated 
lactate dehydrogenase (LDH) [88], [89].
About 36% of ARDS cases are mild, 45% cases 
are moderate while 18.9% cases are severe [17]. Mortality 
increases with the severity of the disease. Patients above 
65 years of age do have worse degree of ARDS and 
they also have higher mortality likelihood [89]. Medical 
laboratory markers that can predict the mortality of 
COVID-19 ARDS patients include low albumin, elevated 
blood urea nitrogen, and elevated LDH [88], [89].
Myocardial injury
Most commonly causes of COVID-19 related 
deaths are usually associated with the hearts and 
lungs [90]. There are two main theories explaining the 
mechanism by which myocardial injury occurs with 
COVID-19. The first theory explains that the heart 
has similar ACE2 levels as that of the lungs [77], 
which allows viral entry into the myocardial cells [91]. 
The second theory involves a cytokine storm causing 
myocardial injury [91]. Myocardial injury includes 
heart failure, myocarditis, acute coronary syndrome, 
hypotension, or shock and sepsis [92]. To have a 
definitive characterization of the injury, endocardial 
biopsy is possibly required and magnetic resonance is 
required [92].
Arrhythmias have been observed to arise 
with severe COVID-19 cases [93], [94]. Malignant 
arrhythmias, including ventricular tachycardia and 
fibrillation, always occur at a rate of 6% and can be 
elevated more frequently in patients with elevated 
troponin levels (17.3% of patients with elevated 
troponin) [85]. Heart failure is commonly observed in 
severe cases of COVID-19, irrespective of previous 
cardiac history [85]. This presents with elevated levels of 
N-terminal pro B-type natriuretic peptide (NT pro-BNP) 
and troponin levels, mostly in severe cases [49]. Some 
studies have also revealed that pulmonary hypertension 
which causes right heart failure can also contribute to 
these cases.
Elevated high sensitivity troponin (HS-troponin) 
and creatinine kinase-myocardial brand (CK-MB) levels 
can also self-sufficiently predict severe COVID-19 
cases [88], [92], [93], [94], [95]. A recent meta-analysis 
revealed that troponin is more elevated in severe 
cases [96]. Cytokines do not predict severity [88]. It has 
been revealed that patients with elevated HS-troponin 
(˃28 ng/L) and CK-MB are suspected to have 
myocarditis or heart failure [7], [88].
Acute kidney injury
Acute kidney injury presents with elevated 
urea and cystatin-C levels in severe COVID-19 
infection [89]. Concerning the cause of acute kidney 
injury, there are two hypotheses to it. One of the 
hypotheses is from kidney able to harbor more ACE-2 
levels than the lung or heart, most especially in the 
proximal convoluted tubules. However, COVID-19 RNA 
is not encountered in the urine. The second theory 
has to do with the injury incurred through a cytokine 
storm [96]. Patients may need to do continuous renal 
replacement therapy (CRRT) due to the severity of 
kidney injury. Speculation exists concerning CRRT 
potentially serving as a way of removing large cytokine 
levels from the system, regardless of kidney injury [96].
The prognosis predictors of COVID-19 
infection include cardiovascular disease, hypertension, 
cerebrovascular disease, and chronic kidney 
disease [48] which can all result in severe conditions. In 
patients with cardiovascular disease, they present with 
a 10.5% coronary flow reserve (CFR); other diseases 
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that can also present with a high CFR include chronic 
lung diseases (6.3%); cancer (5.6%); hypertension 
(6.0%); and diabetes.
Conclusion
The diagnostic analysis of this new infection is 
majorly by NAAT such as real time RT-PCR followed by 
nucleic acid sequencing. Although some serologic and 
immunologic assays such as ELISA and ICG lateral flow 
assay have been developed which detects the IgM and 
IgG antibodies, there are still lots of cautious remarks 
on the direct adoption of these tests due to the need for 
more studies to determine the immunologic capabilities 
and strength of the antibodies in prevention of future 
infection. Based on severity, the laboratory features of 
COVID-19 infection include lymphopenia, eosinopenia, 
reduced procalcitonin along with leucocytosis, 
increased D-dimer, CRP, SAA, fibrin, FDP with mild to 
moderate increase in PT, and APTT while the major 
pathologic presentations present with features of acute 
respiratory syndrome, myocardial injury, and acute 
kidney injury. Furthermore, some inflammatory markers 
such as IL-2,IL-6, IL-7, IL-10, GCSF, MCP10, IP10, 
and TNF-α are apparently increased in COVID-19 
infection signaling cytokine storm in the course of the 
infection and associated SIC. Therefore, as much as 
there are some established pathologies, diagnosis, and 
laboratory features of COVID-19 by clinical presentation 
and hospitalization, more studies are required to identify 
the capabilities, characteristics and tendencies of this 
novel virus as well as the most efficient prevention and 
treatment.
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